[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.168.87. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
August 10, 2011

Genomic Technology Applied to Pharmacological Traits

Author Affiliations

Author Affiliations: Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee (Dr Yang); and Division of Rheumatology, Immunology, and Allergy and Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts (Dr Plenge).

JAMA. 2011;306(6):652-653. doi:10.1001/jama.2011.1125

Advances in genomic technologies have enabled a deeper understanding of a variety of phenotypes relevant to clinical medicine. The ability to test hundreds of thousands of inherited genetic markers for association with medical traits (genome-wide association studies, or GWAS) has led to new discoveries. While GWAS of diseases focus on disease onset and rate of progression, the term pharmacogenomics refers to the application of GWAS and related genomic technologies to understanding variability in treatment outcome of a disease (a drug's efficacy or toxicity).

First Page Preview View Large
First page PDF preview
First page PDF preview
×